Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs

被引:17
作者
Jorgensen, KH [1 ]
Hansen, AK
Buschard, K
机构
[1] Kommunehosp, Bartholin Inst, DK-1399 Copenhagen, Denmark
[2] Royal Vet & Agr Univ, Dept Pharmacol & Pathobiol, Lab Anim Sci & Welf, Copenhagen, Denmark
关键词
absorption; insulin; concentration; NPH; semilente;
D O I
10.1016/S0168-8227(00)00196-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human NPH U100 (100 IU/ml), given once daily, is often absorbed too fast to cover the basal insulin demand throughout 24 h. The aim of the present study was to examine whether the absorption of human insulin suspensions would be delayed by increasing the insulin concentration from U100 to U500. In each experiment 10 IU of corresponding human U100 and U500 preparations, labelled with I-125-insulin, were injected subcutaneously and contralaterally in the neck of a pig followed by monitoring residual radioactivity over the injection sites. The time until 75, 50 and 25% residual radioactivity (T-75%, T-50% and T-25%) using NPH U500 was compared with NPH U100 in 14 experiments: T-75%: 5.0 +/- 0.5 (mean +/- SEM) vs 3.8 +/- 0.3 h (P = 0.007, paired t-test), T-50%: 12.2 +/- 0.9 vs 9.0 +/- 0.6 h (P = 0.003) and T-25%. 24.2 +/- 1.2 vs 17.9 +/- 1.2 h (P = 0.001). The corresponding values for semilente U500 compared with semilente U100 in eight experiments were: T-75%: 2.8 +/- 0.4 vs 1.6 +/- 0.2 h (:P = 0.02), T-50%: 5.6 +/- 0.6 vs 3.4 +/- 0.3 h (P = 0.01) and T-25%: 10.9 +/- 1.1 vs 7.2 +/- 0.7 h (P = 0.009). Thus, the absorption of a given dose of human NPH or human semilente insulin in pigs is substantially delayed by changing the insulin concentration from U100 to U500. Human NPH U500 appears to be more appropriate than human NPH U100 for injection once daily in basal insulin therapy. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 17 条
[1]   Insulin analogues [J].
Barnett, AH ;
Owens, DR .
LANCET, 1997, 349 (9044) :47-51
[2]   ABSORPTION KINETICS AND BIOLOGIC EFFECTS OF SUBCUTANEOUSLY INJECTED INSULIN PREPARATIONS [J].
BERGER, M ;
CUPPERS, HJ ;
HEGNER, H ;
JORGENS, V ;
BERCHTOLD, P .
DIABETES CARE, 1982, 5 (02) :77-91
[3]   ABSORPTION KINETICS OF SUBCUTANEOUSLY INJECTED INSULIN - EVIDENCE FOR DEGRADATION AT THE INJECTION SITE [J].
BERGER, M ;
HALBAN, PA ;
GIRARDIER, L ;
SEYDOUX, J ;
OFFORD, RE ;
RENOLD, AE .
DIABETOLOGIA, 1979, 17 (02) :97-99
[4]  
BINDER C, 1969, ABSORPTION INJECT IN
[5]   Insulin analogues and their potential in the management of diabetes mellitus [J].
Bolli, GB ;
Di Marchi, RD ;
Park, GD ;
Pramming, S ;
Koivisto, VA .
DIABETOLOGIA, 1999, 42 (10) :1151-1167
[6]  
Council of Europe, 1986, 123 ETS COUNC EUR
[7]  
Hansen AK, 1998, SCAND J LAB ANIM SCI, V25, P145
[8]  
HEINEMANN L, 1992, DIABETES METAB, V18, P21
[9]   THE ABSORPTION OF SUBCUTANEOUSLY INJECTED SHORT-ACTING SOLUBLE INSULIN - INFLUENCE OF INJECTION TECHNIQUE AND CONCENTRATION [J].
HILDEBRANDT, P ;
SESTOFT, L ;
NIELSEN, SL .
DIABETES CARE, 1983, 6 (05) :459-462
[10]  
HILDEBRANDT P, 1984, ACTA MED SCAND, V215, P6973